Cellectis S.A.
CLLS Healthcare Biotechnology
Cellectis S.A.’s revenue for fiscal 2025 (year ended December 2025) was $79.6 million, up 61.7% from fiscal 2024. In the quarter to June 2026, revenue fell 62.1%, EPS grew 8.33%, free cash flow fell 37.0% and total debt was flat, each against the same quarter a year earlier.
Follow CLLS
Cellectis S.A. (CLLS) Altman Z-score
Cellectis S.A.'s Altman Z-score for fiscal 2025 is −0.03, in the distress zone (below 1.81).
Altman Z-score, annual
Embed this chart
Annual newest first
| Period | Altman Z-score | Change (points) |
|---|---|---|
| FY2025 | −0.03 | 0.80 |
| FY2024 | −0.82 | 1.11 |
| FY2023 | −1.93 | 0.66 |
| FY2022 | −2.59 | (1.30) |
| FY2021 | −1.30 | (4.09) |
| FY2020 | 2.79 | 0.40 |
| FY2019 | 2.39 | (4.94) |
| FY2018 | 7.33 | (4.14) |
| FY2017 | 11.47 | 5.88 |
| FY2016 | 5.59 | (1.94) |
How fiscal 2025’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Working capital / total assets | 0.28 | — | 0.33 | |
| Retained earnings / total assets | (1.03) | — | −1.44 | |
| EBIT / total assets | (0.10) | — | −0.34 | |
| Market value of equity / total liabilities | 1.95 | — | 1.17 | |
| Sales / total assets | 0.25 | — | 0.25 | |
| Altman Z-score | Distress zone | −0.03 | ||
| Z″ Variant for non-manufacturing and asset-light companies (drops the sales/assets term, uses book equity) | Distress zone | −1.89 | ||
How the Altman Z-score works
Z = 1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets (Altman, 1968). The market value of equity is the close on the last trading day of the fiscal year times weighted basic shares.
Z″ = 6.56 × working capital ÷ total assets + 3.26 × retained earnings ÷ total assets + 6.72 × EBIT ÷ total assets + 1.05 × book equity ÷ total liabilities (Altman, Hartzell and Peck, 1995), the variant for non-manufacturing and asset-light companies.
| Zone | Z | Z″ |
|---|---|---|
| Safe zone | above 2.99 | above 2.60 |
| Grey zone | 1.81–2.99 | 1.10–2.60 |
| Distress zone | below 1.81 | below 1.10 |
Not worked out for banks, insurers and REITs, whose balance sheets the model does not describe, nor when a figure is missing or there is no share price in the week to the fiscal year end.
Altman Z-score against peers
| Company | Altman Z-score |
|---|---|
| NTRB Nutriband Inc. compare | 27.2× |
| CLLS Cellectis S.A. | 0.0× |
| PTHS Pelthos Therapeutics Inc. compare | −0.8× |
| CRBP Corbus Pharmaceuticals Holdings, Inc. compare | −4.1× |
| EQ Equillium, Inc. compare | −6.8× |
| PMN Promis Neurosciences compare | −78.9× |
| TELO Telomir Pharmaceuticals, Inc. compare | — |
| AARD Aardvark Therapeutics, Inc. compare | — |
| NMRA Neumora Therapeutics, Inc. compare | — |
What Altman Z-score is
The Altman Z-Score weighs working capital, retained earnings, operating profit, market value and sales against assets and debts to gauge the risk of distress.
1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets